Adeza Gestiva NDA for preterm birth
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Adeza is requesting a priority review of its Gestiva (17 alpha-hydroxyprogesterone caproate) NDA for prevention of preterm birth in women with a history of preterm delivery, the firm says May 4. The NDA is based on a study conducted by the National Institutes of Health. Gestiva is a long-acting, naturally occurring form of progesterone. "If Gestiva is approved, Adeza will have the only commercially available, NIH-studied, ACOG-recommended" treatment for the indication, Adeza said...
You may also be interested in...
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: